Agilon Health Inc. Reports Q1 2026 Results: A Mixed Bag of Challenges and Opportunities
Agilon Health Inc., a frontrunner in healthcare transformation, has released its financial results for the first quarter of 2026. The company, which specializes in empowering primary care physicians (PCPs) through innovative, value-based care models, is navigating a landscape of challenges while also showcasing areas of significant improvement.
1. Overview of Recent Developments
Agilon Health continues to evolve its business model, focusing on forming risk-bearing entities (RBEs) that manage total healthcare needs for attributed patients through global capitation arrangements. This approach aims to enhance quality, cost, and patient experience. However, the company faced some headwinds in Q1 2026, leading to a decrease in membership and total revenue.
Key Developments
- Reverse Stock Split: On March 30, 2026, Agilon executed a 1-for-25 reverse stock split, reclassifying shares of common stock. This move was strategic, aiming to enhance the company's stock price and improve its marketability.
- CEO Appointment: Tim O’Rourke has been appointed as the new Chief Executive Officer and President, expected to start on May 7, 2026. His leadership is anticipated to steer the company through its current challenges.
2. Financial Performance Overview
Revenue and Income Highlights
Agilon reported total revenue of $1.4 billion for Q1 2026, a 7% decrease compared to the same period in 2025. Despite the decline in revenue, gross profit rose to $65 million, an increase from $51 million year-over-year. The medical margin also improved, reaching $149 million, up from $128 million in the previous year. Most notably, net income surged to $49 million, a significant rise from just $12 million in Q1 2025.
| May 2025 | May 2026 | |
|---|---|---|
Net Income | -241.9M | -354.5M |
Net Income to Non-controlling Interest | 20K | 0 |
Profit | -241.9M | -354.5M |
Net Income Discontinued | 12.93M | 19M |
Net Income Continuing | -255.4M | -373.5M |
Income Tax Expense | 1.78M | 1.08M |
Pretax Income | -253.6M | -372.4M |
Non-operating Income | 53.43M | 64.66M |
Operating Income | -307.0M | -437.1M |
Revenue | 5.98B | 5.82B |
Costs and Expenses | 6.29B | 6.25B |
Cost of Revenue | 6.00B | 5.96B |
Operating Expenses | 287.5M | 291.4M |
Depreciation, Depletion & Amortization | 25.49M | 28.50M |
Impairment Expense | 3.59M | 36.08M |
Selling, General & Administrative | 258.4M | 226.8M |
Membership Trends
The company faced a 13% decrease in Medicare Advantage (MA) members, with membership falling to 426,300 as of March 31, 2026. This decline is attributed to market exits and a disciplined contracting approach focused on profitability. Additionally, Agilon maintains 109,500 beneficiaries attributed to CMS ACO Models.
3. Expense Management
Agilon successfully reduced its medical services expenses by 9%, totaling $1.35 billion in Q1 2026. This decrease was primarily driven by the drop in MA membership, alongside positive claims development from the latter half of 2025.
Breakdown of Expenses
- Other Medical Expenses: Increased by 7% to $58.5 million, largely due to higher partner physician incentive expenses.
- General and Administrative Expenses: Saw a notable decline of 18%, amounting to $54.23 million, reflecting effective cost management initiatives.
| May 2025 | May 2026 | |
|---|---|---|
Net Change in Cash | 20.07M | 72.94M |
Net Cash from Operating Activities | -41.98M | -50.04M |
Operating Profit | -241.9M | -354.5M |
Adjustment to Operating Profit | 199.9M | 304.4M |
Net Cash from Investing Activities | 65.36M | 130.9M |
Investments | -102.9M | -166.3M |
Productive Assets | 37.59M | 35.35M |
Net Cash from Financing Activities | -3.30M | -7.98M |
Debt | -2.5M | -3.5M |
Equity Issuance/Repurchase | -803K | -2.86M |
Other Financing Activities | 0 | -1.61M |
4. Balance Sheet Snapshot
As of March 31, 2026, Agilon's total assets stood at $1.50 billion, down from $1.93 billion in 2025. This reduction is reflective of the company's strategic decisions and ongoing adjustments in its operations. The company holds $211.6 million in cash and cash equivalents, alongside $91.4 million in marketable securities.
| May 2025 | May 2026 | |
|---|---|---|
Total Assets | 1.93B | 1.50B |
Total Current Assets | 1.65B | 1.32B |
Cash and Equivalents | 136.9M | 139.9M |
Short-term Investments | 230.1M | 91.42M |
Restricted Cash and Investments | 1.68M | 71.57M |
Prepaid Expenses | 42.35M | 118.4M |
Total Non-current Assets | 282.1M | 183.7M |
Intangible Assets | 92.28M | 62.44M |
Net PP&E | 28.08M | 24.88M |
Other Non-current Assets | 161.7M | 96.43M |
Total Liabilities and Equity | 1.93B | 1.50B |
Total Liabilities | 1.43B | 1.32B |
Total Current Liabilities | 1.37B | 1.27B |
Accounts Payable and Accrued Liabilities | 226.6M | 202.4M |
Current Debt | 34.92M | 14.74M |
Other Current Liabilities | 1.11B | 1.05B |
Total Non-current Liabilities | 57.90M | 51.18M |
Long-term Debt | 0 | 15.27M |
Other Non-current Liabilities | 57.90M | 35.90M |
Total Equity and Non-controlling Interests | 500.2M | 181.4M |
Total Equity | 499.7M | 180.9M |
5. Cash Flow and Liquidity
The company reported a net change in cash of $37.85 million for Q1 2026, a significant turnaround from a negative cash flow of $55.23 million in the same period of 2025. The improvement in cash flow is attributed to better operating profits and strategic financing activities.
6. Looking Ahead
Agilon Health Inc. is poised for a transformative year ahead, especially under the leadership of Tim O’Rourke. The company is committed to refining its operations and enhancing its partnerships in the healthcare ecosystem. With a focus on profitability and sustainable growth, Agilon is determined to overcome the hurdles it currently faces.
Conclusion
While Agilon Health Inc. experienced a decrease in revenue and membership in Q1 2026, the significant improvement in net income and effective expense management highlights its resilience. As it embarks on a new chapter with a new CEO, the company remains dedicated to its mission of enhancing healthcare through innovative solutions. Investors and stakeholders will be keenly watching how Agilon navigates the complexities of the healthcare market in the coming quarters.
